**Results.** A total of 410 IPD cases were identified. The cumulative incidence of IPD (0-22 years of age) decreased from 99.2/100,000 admissions in 2017-2019 to 53.8/100,000 admissions in 2020 (risk ratio 0.54, CI: 0.40-0.72, p < 0.0001). Pneumococcal bacteremia and pneumonia decreased significantly in 2020 (p < 0.05), and although not statistically significant, there were fewer cases of meningitis and mastoiditis when compared to previous years (p=0.08) (Figure 1). Sex, age or presence of comorbidities were not significantly different between groups. Most common serotypes in 2020 were 35B, 3 and 15B/C (Figure 2).

**Methods.** We identified erythromycin-resistant (R) (minimum inhibitory concentration [MIC] ≥ 1 µg/mL) and clindamycin-susceptible (S) (MIC ≤ 0.25 µg/mL) pneumococcal isolates from pediatric patients seen at Children’s Mercy Hospital from 2007 to 2017. Determination of ICR was achieved via disk approximation (D-zone test) with standard erythromycin (15 µg) and clindamycin (2 µg) disks. Isolates with high-level erythromycin resistance (MIC ≥ 32 µg/mL) were also tested for ermA gene by PCR. Positive and negative controls were used for D-zone test and ermA PCR.

**Results.** We identified 289 erythromycin-R pneumococcal isolates; of those 194 (67.1%) were clindamycin-S (Figure 1). One-hundred and sixty-nine isolates were available for ICR testing, 166 (98%) isolates represented non-invasive disease samples. Median age of patients with erythromycin-R and clindamycin-S isolates was 19 (range 0.1 – 180) months. None of the isolates expressed ICR based on the D-zone test. Thirteen of those isolates (7.7%) expressed high-level erythromycin resistance (MIC range 32-128 µg/mL); all were negative for ermA. The most common serotypes/serogroups among erythromycin-R and clindamycin-S isolates were: 15 (n=22), 35B (n=19), 11 (n=16), 6 (n=16), 19A (n=14) and 33 (n=12).

**Conclusion.** Erythromycin-R and clindamycin-S pneumococcal isolates did not express ICR and isolates with high-level erythromycin-R did not carry ermA. Multicenter studies are needed to determine if ICR testing is required for macrolide-resistant pneumococcal isolates in the PCV13 era.

**Disclosures.** Sheldon L. Kaplan, MD, Pfizer (Research Grant or Support); Tina Q. Tan, MD, GSK (Individual(s) Involved: Self); Jennifer E. Tabahk, Microbiology; Maria E. Cervantes, BVSc, PhD1; Children’s Mercy Hospital, Kansas City, Missouri; Larry Givner, MD, Pfizer (Research Grant or Support); Kristina G. Hulten, PhD, Pfizer (Research Grant or Support).

185. Trends in Clinical Presentation and Antibiotic Resistance of Viridans Group Streptococci Bloodstream Infections in Immuno compromised Children

Ana M. Quintero, MD2; Diego A. Cruz Vidal, MD - Fellow3; Monica L. Ardura, DO, MSc3; Sophonie Jean, PhD3; Nationwide Children’s Hospital, Columbus, OH

**Session:** O-36. Trends in Pediatric Bacterial Disease

**Background.** Levofloxacin prophylaxis (LVXP) is recommended in children with severe neutropenia from underlying malignancy or hematopoetic cell transplantation (HCT). The impact of LVXP on the epidemiology of viridans group streptococci bloodstream infections (VGS-BSI) is unknown. At our center, LVXP was prescribed to high-risk children with expected prolonged neutropenia (ANC < 100, > 7 days) as part of a clinical trial (2013-17) and routinely since November 2018. We aim to describe our local epidemiology, antibiotic susceptibilities, and clinical outcomes of VGS-BSI over time.

**Methods.** VGS-BSI from 1/1/10 to 3/31/21 were identified via the laboratory database. Clinical data of patients followed at NCH with underlying malignancy, severe neutropenia, or HCT were extracted from the electronic health record. Available VGS isolates were subcultured, species identification confirmed by MALDI-ToF or 16s rDNA sequencing and susceptibility to penicillin (PCN), cefepime (CEF), vancomycin (VAN), and LVXP performed via Etest per CLSI M100 guidelines. Non-parametric descriptive statistics were applied.

**Results.** Over a 10-yr period, 111 VGS-BSI occurred in 93 patients (Table 1); 15 (16%) patients had ≥ 2 VGS-BSI. 80 (86%) patients had fever and neutropenia (FN); 26 (28%) required ICU care for vasopressors (N=17, 18%) or mechanical ventilation (N=10, 11%). Most VGS isolates were S. mitis/oralis group. In total, 15 (16%) patients received LVXP ≤ 6 months before VGS-BSI; 9 (10%) had breakthrough VGS-BSI while receiving LVXP and all isolates were LVX resistant. Figure 1 shows susceptibilities: overall, 24% of isolates had frank resistance to PCN, 19% CEF, 13% LVX; all were VAN susceptible. When evaluating for changes in susceptibilities over time, there was a significant difference in the proportion of LVX-resistant isolates (p=0.009, Cochran-Armitage χ²), but not CEF (p=0.08) or PCX (p=0.86).
Table 1. Demographic and Clinical Characteristics of Immunocompromised Children with Viridans Group Streptococci Bloodstream Infections (VGS-BSI)

| Variable                        | N=93 patients |
|---------------------------------|---------------|
| Age, in years (median, [IQR])   | 6.2 [0.0-13.9]|
| Male sex (N, %)                 | 58 (51%)      |
| Underlying condition (N, %)     |               |
| Leukemia                        | 43 (46%)      |
| Acute myelogenous leukemia (AML) | 21 (22%)     |
| Acute Lymphoblastic Leukemia (ALL) | 22 (24%)   |
| Hematopoietic cell transplantation (HCT) | 21 (22%)   |
| Allergic (allo-HCT)             | 14 (15%)      |
| Autologous (auto-HCT)           | 7 (8%)        |
| Central Nervous System tumors   | 8 (9%)        |
| Sarcina                         | 14 (15%)      |
| Other                           | 10 (11%)      |
| Absolute neutrophil count (ANC, in mm\(^3\), median, [IQR]) | 0 cells [0-38] |
| Mucoritis at time of VGS-BSI (N, %) | 27 (29%) |
| Time to bacteremia from hospital admission, in days, (median, [IQR]) | 10 [1-16] |
| Time to blood culture positivity, in hours, (median, [IQR]) | 15 [12-16.5] |
| Time to sterilization of blood culture, in days, (median, [IQR]) | 1 [0-2] |
| Empirical antibiotic therapy in first 24 hours, N (%) | 21 (22%) |
| - B-lactam monotherapy          | 68 (73%)      |
| - Combination therapy, including vancomycin | 4 (4%)  |
| - Other                         | 20 (21%)      |
| Duration of total antibiotic therapy, in days, (median, [IQR]) | 14 [10-15] |
| Duration of hospitalization, in days, (median, [IQR]) | 9 [5-9.5] |
| Identification of VGS, N (%)    |               |
| - S. mitis/brasil group         | 70 (84%)      |
| - S. salivarius                 | 7 (8%)        |
| - S. parasanguinis              | 2 (2%)        |
| - S. sanguis                   | 2 (2%)        |
| - S. gordoni                   | 2 (2%)        |

*49/111 (45%) VGS-BSI were available for testing

Conclusion. Breakthrough, LVX-resistant VGS-BSI occurred in 10% of patients, most frequently in children with AML or HCT. Over time, there was a trend towards increased LVX resistance in the cohort. Routine antimicrobial testing and ongoing monitoring for emergence of resistance are warranted to inform local prophylaxis and empirical antibiotic strategies for high-risk children with FEN.

Disclosures. Monica I. Aruda, DO, MSCS, Shire (Grant/Research Support)

186. Characteristics of COVID-19 Vaccine Breakthrough Cases in Minnesota, 2021

Stephanie Meyer, MPH\(^1\); Amy Saape, MPH\(^1\); Aaron Bieringer, MPH\(^1\); Corrine Holtzman, MPH\(^1\); Luke Magnuson, MPH\(^1\); Erica Bye, MPH\(^1\); Miriam Muscoplat, MPH\(^1\); Xiong Wang, DVM, PhD\(^3\); Alexandra Locato, PhD\(^3\); Kathryn Como-Sabetti, MPH\(^1\); Ruth Lynfield, MD\(^3\); Ruth Lynfield, MD\(^3\); 1Minnesota Department of Health, Minneapolis, Minnesota

Session: O-37. Updates in COVID Epidemiology

Background. Over 600,000 COVID-19 cases, including >7000 deaths reported to MN Dept of Health (MDH) by June 1, 2021. Clinical trials demonstrated high effectiveness of COVID vaccines. We assessed COVID-19 cases among fully vaccinated residents [vaccine breakthrough (VB) cases].

Methods. COVID-19 VB cases were MN residents with completed COVID-19 vaccination series ≥14 days prior to symptom onset or positive for SARS-CoV-2 by nucleic acid amplification or antigen test. COVID-19 cases were reported to MDH and COVID-19 vaccinations reported to the MN Immunization Information Connection (MIIC). COVID-19 cases were matched to MIIC to identify VB and interviewed; medical records of hospitalized cases were reviewed. Available VB case specimens underwent whole genome sequencing (WGS) at MDH or collaborating lab.

Results. Jan 19 – June 1, 2021, 2765 VB cases were reported among ~2.45 million fully vaccinated residents and 147,445 COVID-19 cases. VB case median (MEd) age was 52 y (IQR 38, 68), 83% white, 65% female; MED age of fully vaccinated was 55 y (IQR 30, 68), 77% white, 54% female. Of VB cases, 273 (10%) were hospitalized and 32 (1%) died (MED age 74 y; IQR 66, 85). 2212 (80%) VB cases were interviewed; 60% reported symptoms; most common were fatigue (53%), rhinorrhea (48%), cough (42%), headache (41%), 35% reported a comorbidity.

Of hospitalized VB cases, 120 had completed record reviews. 64 were admitted for COVID-19 related illness (MEd age 74 y; IQR 65, 83) including 27 admitted to ICU (MEd age 71 y; IQR 67, 83); 90% (108) reported a comorbidity, most common being chronic metabolic conditions (46%), obesity (45%), renal disease (31%) and chronic lung disease (26%); 27 were immunocompromised (not mutually exclusive), including immunosuppressive therapy (15%), hematological malignancy (9), other cancer (11), and organ transplant recipients (8).

Of 604 VB case specimens, 79% were B.1.1.7, 9% B.1.427/429, 3% P.1, and 2% B.1.351; lineage distribution was similar to overall 24,157 MN SARS-CoV2 WGS data. Conclusion. Identified VB cases were 0.1% of those vaccinated and < 2% of total cases reported in the time period. COVID-19 vaccines are an important tool in preventing COVID-19. Additional surveillance, including WGS and case characteristics will be useful to monitor VB.

Disclosures. Ruth Lynfield, MD. Nothing to disclose.

187. Characterizing Household Clustering of COVID-19 Cases in Fulton County, Georgia, June 2020–April 2021

Carol Liu, MS\(^2\); Sasha Smith, MPH\(^1\); Allison Chamberlain, PhD\(^3\); Neel Gandhi, MD\(^3\); Fazle N. Khan, MBBS, DPH, MPH\(^1\); Steve Williams, M Sc\(^4\); Sarita Shah, MD\(^5\); Emory University, Atlanta, Georgia; Fulton County Board of Health, Atlanta, Georgia; Rollins School of Public Health, Atlanta, Georgia; Georgia Dept. of Public Health, Atlanta, Georgia; Fulton County, Atlanta, Georgia

Session: O-37. Updates in COVID Epidemiology

Background. Households are important for SARS-CoV-2 transmission due to close proximity in enclosed living spaces over long durations. Using contact tracing, the secondary attack rate in households is estimated at 18-20%, yet no studies have examined COVID-19 clustering within households, an important measure to inform testing and prevention. We sought to quantify and characterize household clustering of COVID-19 cases in Fulton County, Georgia.

Methods. We used state surveillance data to identify all PCR- or antigen-confirmed cases of COVID-19 in Fulton County. Clustered cases were defined as cases with matching address, including unit number. Communal places (e.g., nursing homes, correctional facilities) were excluded, as were apartments missing unit number. Household samples were defined as ≥2 COVID-19 cases at the same residential address with positive sample collection dates within 14 days of one another. We described proportion of COVID-19 cases that were clustered, stratified by age, sex, and race/ethnicity over time.

Results. There were 60,614 COVID-19 cases with available address reported in Fulton County during 6/1/20–4/30/21. Of these, 25,149 (41.6%) had an address that matched at least one other case; 20,793 (34.3%) were from 8,582 household clusters defined as households with positive sample collection dates within 14 days (Fig 1). Majority of clusters had 2 individuals (N=6119, 71%), though some had 26 individuals (N=79, 8.9%). Clustering increased through January 2021 (Fig 2). Children were more likely to be in household clusters (Fig 4) and 15% of clusters had a child as first diagnosed case with increases since January 2021 (Fig 3). Consistently higher clustering was observed among Hispanic persons, with rising clustering among Asian persons (Fig 5).

Figure 1. Distribution of household clustered COVID-19 cases.